Senior Post-doctoral Fellow in Immuno-Oncology Research - BJ0723

The revolution of cancer immunotherapy based on Immune-checkpoint inhibitors (ICIs) is in the process of fundamentally reshaping the treatment of cancer. This enthusiastic vision has been seriously challenged by the clinical reality that only a few patients benefit from the remarkable clinical remissions whereas the majority have a short-term benefit or no benefit at all. To broaden the use of immunotherapy, immune-oncology research is now pushing towards rationally combining immunotherapy with other therapies.
Rue Nicolas-Ernest Barblé 6A, Luxembourg L-1210, Luxembourg
10/01/2024 09:38:00

In partnership with several pharma companies, our group focuses on defining targets or pathways in the tumor microenvironment that are involved in impairing the anti-tumor immune response and compromising the effect of ICIs. Our aim is to develop innovative molecules that can be combined with ICIs to improve/extend their benefit and to provide the preclinical proof of concept to set up innovative clinical trials in collaboration with our partners.  


TIME is a dynamic and multinational translational research group operating in the Department of Cancer Research at LIH. TIME research activities are at the forefront of translating basic knowledge into clinical application. The strategic priority of the TIME group relies on generating basic cutting-edge knowledge through discovering and defining druggable gene targets in tumor cells and key pathways in the tumor microenvironment able to reprogram cold immune desert tumors, not eligible for immune checkpoint inhibitors, into hot inflamed immune infiltrated tumors, which are eligible to immune checkpoint inhibitors. TIME is a highly skilled research group recognized to be a driving force in conducting world-class translational research relying on the “Bench to Bedside to Clinical Practice” concept through a network collaboration with Pharma and Biotech companies. More information about the group can be found here:


In addition to an attractive salary, the successful candidate will join a highly dynamic research environment and get access to several core facilities and relevant state-of-the-art technologies. She/he will benefit from a wide range of cutting-edge technologies, including genomic, transcriptomic, and proteomic analyses, as well as in vitro and in vivo imaging modalities using state-of-the-art animal models for cancer research. In addition, the candidate will have access to outstanding seminar programs, international conference attendance, and opportunities to collaborate with biotech and pharma companies. The following profile is required for this position: 

PhD in Cellular and Molecular Biology or Oncology with strong expertise in cancer immunology.  

Strong skill in animal experimentation (FELASA authorization, or equivalent, to work with mice is mandatory); comprehensive immune landscape profiling using CyTOF; RNAseq and scRNAseq; handling large multi-omics data sets; molecular biology and cell imaging techniques.

The candidate should have an experience in pharma industry. 

Independent and self-motivated person, scientific creativity and originality, strong team spirit and collaborative capacity, excellent time management, rigor, perseverance, and strong writing skills. 

Fluency in English is mandatory.

Major publications: 

Lequeux et al., Oncogene 2021.

Noman et al., Science Advances 2020.

Mgrditchian et al., PNAS 2017

Baginska et al., PNAS 2013

Noman, Janji et al., Cancer Res. 2011


  • Contract type:          3-year fixed-term contract
  • Work hours:               Full-time
  • Location:                    Strassen
  • Start date:                 September 2023 
  • Ref:                              MC/SPDR0723/BJ/TIME


Candidates can apply by submitting a cover letter and curriculum vitae through our website REF: MC/SPDR0723/BJ/TIME

or directly to the scientific contact:

Dr. Bassam Janji (PhD, HDR)

Luxembourg Institute of Health

Department of cancer Research. 

All interested candidates irrespective of age, gender, race, disability, religion or ethnic background are encouraged to apply.


The LIH is an equal opportunities employer.
 We are fully committed to removing any discriminatory barrier related to gender, and not only, in recruitment and career progression of our staff.

The LIH is attentive to gender representation among its leadership staff and aims to eliminate obstacles to the recruitment and promotion of female leaders and their career development.